Seagen Inc. Overview
Pro stress-test →Seagen, acquired by Pfizer in one of the largest investments in Pfizer's history, is a leader in antibody-drug conjugate (ADC) technology for cancer treatment. With the acquisition, Pfizer doubled its oncology pipeline to 60 products, with nine of them blockbusters or potential blockbusters. The company now operates as a Pfizer subsidiary focused on advancing innovative cancer therapies.
Strategic Profile
Pro stress-test →Pfizer is focused on delivering transformative therapies in some of the world's most common cancers: breast cancer, across hormonal subtypes; genitourinary cancer, including prostate and bladder cancer; hematology-oncology, including multiple myeloma and lymphomas, such as Hodgkin's disease; and thoracic cancers, which includes lung cancer. Seagen contributed four FDA-approved cancer drugs—Adcedris, Padcev, Tivdak and Tukysa—that have blockbuster or blockbuster potential.
Competitive Landscape
Pro stress-test →Seagen operates in the highly competitive oncology antibody-drug conjugate space. Key competitors include other ADC developers and broad-spectrum oncology companies with complementary mechanisms. Pfizer's industry-leading portfolio includes three core mechanisms of action to treat cancer: small molecules, ADCs and bispecific antibodies, including other immune-oncology biologics, positioning Seagen within a differentiated but contested market.
Industry Context
Seagen Inc. operates in Oncology antibody-drug conjugates (ADCs).
Key facts
Headquarters: Bothell, US